Literature DB >> 25216543

Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.

Michal Lipš1, Michal Siller2, Jan Strojil2, Karel Urbánek2, Martin Balík1, Hana Suchánková3.   

Abstract

In critically ill patients, pathophysiological changes alter the pharmacokinetics of antibiotics. Imipenem exhibits primarily time-dependent killing. Its administration by prolonged infusion may increase the time for which its plasma concentration exceeds the minimum inhibitory concentrations (MICs) of suspected pathogens. The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0.5g imipenem/0.5g cilastatin over 3h four times daily) and to compare the target pharmacokinetic/pharmacodynamic indices, namely percentage of the dosing interval for which the free plasma concentration of imipenem exceeds the MIC and 4× MIC (%fT>MIC and %fT>4×MIC) of 0.5, 1, 2 and 4mg/L, for these two regimens in critically ill adult patients with nosocomial pneumonia on Day 2 of empirical antibiotic therapy. The study included 22 patients. Whilst no significant differences were found between both groups for %fT>MIC, %fT>4×MIC was 87.4±12.19%, 68.6±15.08%, 47.31±6.64% and 27.81±9.52% of the 8-h interval in the short infusion group for MICs of 0.5, 1, 2 and 4mg/L, respectively, and 85.15±17.57%, 53.14±27.27%, 13.55±24.47% and 0±0% of the 6-h interval for the extended infusion group. In conclusion, administration of 0.5g of imipenem by a 3-h infusion every 6h does not provide sufficient drug concentrations to treat infections caused by pathogens with a MIC of ≥2mg/L.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  ICU; Imipenem; PK/PD; Pneumonia; Prolonged infusion

Mesh:

Substances:

Year:  2014        PMID: 25216543     DOI: 10.1016/j.ijantimicag.2014.05.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 3.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

4.  Imipenem Population Pharmacokinetics: Therapeutic Drug Monitoring Data Collected in Critically Ill Patients with or without Extracorporeal Membrane Oxygenation.

Authors:  Wenqian Chen; Dan Zhang; Wenwen Lian; Xiaoxue Wang; Wenwen Du; Zhu Zhang; Dongjie Guo; Xianglin Zhang; Qingyuan Zhan; Pengmei Li
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.

Authors:  Xiaofen Liu; Huajun Zheng; Weipeng Zhang; Zhen Shen; Miao Zhao; Yuancheng Chen; Li Sun; Jun Shi; Jing Zhang
Journal:  Front Microbiol       Date:  2016-08-19       Impact factor: 5.640

Review 6.  Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis.

Authors:  Zhenwei Yu; Xiaoping Pang; Xuqi Wu; Chunlei Shan; Saiping Jiang
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

Review 7.  Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.

Authors:  Ling-Ling Zhu; Quan Zhou
Journal:  Infect Drug Resist       Date:  2018-08-08       Impact factor: 4.003

8.  Prolonged infusion with β-lactam antibiotics for treatment of infection caused by non-susceptible bacteria: a study protocol for a systemic review and meta-analysis.

Authors:  Huadong Chen; Lingyan Yu; Zhenwei Yu
Journal:  BMJ Open       Date:  2019-05-22       Impact factor: 2.692

Review 9.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

10.  Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.

Authors:  Tae Hwan Kim; Xun Tao; Bartolome Moya; Yuanyuan Jiao; Kari B Basso; Jieqiang Zhou; Yinzhi Lang; Dhruvitkumar S Sutaria; Alexandre P Zavascki; Afonso L Barth; Stephanie M Reeve; Herbert P Schweizer; Deanna Deveson Lucas; John D Boyce; Robert A Bonomo; Richard E Lee; Beom Soo Shin; Arnold Louie; George L Drusano; Jürgen B Bulitta
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.